|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
3
|
Olayioye MA, Neve RM, Lane HA and Hynes
NE: The ErbB signaling network: receptor heterodimerization in
development and cancer. EMBO J. 19:3159–3167. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baselga J and Arteaga CL: Critical update
and emerging trends in epidermal growth factor receptor targeting
in cancer. J Clin Oncol. 23:2445–2459. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hynes NE and Lane HA: ERBB receptors and
cancer: the complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Duchnowska R, Biernat W, Szostakiewicz B,
et al: Correlation between quantitative HER-2 protein expression
and risk for brain metastases in HER-2+ advanced breast
cancer patients receiving trastuzumab-containing therapy.
Oncologist. 17:26–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Howe LR and Brown PH: Targeting the
HER/EGFR/ErbB family to prevent breast cancer. Cancer Prev Res.
4:1149–1157. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Modjtahedi H and Essapen S: Epidermal
growth factor receptor inhibitors in cancer treatment: advances,
challenges and opportunities. Anticancer Drugs. 20:851–855. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Serrano-Olvera A, Dueñas-González A,
Gallardo-Rincón D, Candelaria M and De la Garza-Salazar J:
Prognostic, predictive and therapeutic implications of HER2 in
invasive epithelial ovarian cancer. Cancer Treat Rev. 32:180–190.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rubin SC, Finstad CL, Wong GY, Almadrones
L, Plante M and Lloyd KO: Prognostic significance of HER-2/neu
expression in advanced epithelial ovarian cancer: a multivariate
analysis. Am J Obstet Gynecol. 168:162–169. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fire A, Xu S, Montgomery MK, Kostas SA,
Driver SE and Mello CC: Potent and specific genetic interference by
stranded RNA in Caenorhabditis elegans. Nature. 391:806–811.
1998. View Article : Google Scholar
|
|
13
|
Szweykowska-Kulińska Z, Jarmołowski A and
Figlerowicz M: RNA interference and its role in the regulation of
eucaryotic gene expression. Acta Biochim Pol. 50:217–229.
2003.PubMed/NCBI
|
|
14
|
Elbashir SM, Harborth J, Lendeckel W,
Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs
mediate RNA interference in cultured mammalian cells. Nature.
411:494–498. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ueno NT, Bartholomeusz C, Herrmann JL, et
al: E1A-mediated paclitaxel sensitization in
HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis
involving the caspase-3 pathway. Clin Cancer Res. 6:250–259.
2000.PubMed/NCBI
|
|
16
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thompson CB: Apoptosis in the pathogenesis
and treatment of disease. Science. 267:1456–1462. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chuang TC, Hsu SC, Cheng YT, Shao WS, Wu
K, Fang GS, Ou CC and Wang V: Magnolol down-regulates HER2 gene
expression, leading to inhibition of HER2-mediated metastatic
potential in ovarian cancer cells. Cancer Lett. 311:11–19. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yamashita-Kashima Y, Iijima S, Yorozu K,
Furugaki K, Kurasawa M, Ohta M and Fujimoto-Ouchi K: Pertuzumab in
combination with trastuzumab shows significantly enhanced antitumor
activity in HER2-positive human gastric cancer xenograft models.
Clin Cancer Res. 17:5060–5070. 2011. View Article : Google Scholar
|
|
20
|
Tanizaki J, Okamoto I, Fumita S, Okamoto
W, Nishio K and Nakagawa K: Roles of BIM induction and survivin
downregulation in lapatinib-induced apoptosis in breast cancer
cells with HER2 amplification. Oncogene. 30:4097–4106. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Decock J, Thirkettle S, Wagstaff L and
Edwards DR: Matrix metalloproteinases: protective roles in cancer.
J Cell Mol Med. 15:1254–1265. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hua H, Li M, Luo T, Yin Y and Jiang Y:
Matrix metalloproteinases in tumorigenesis: an evolving paradigm.
Cell Mol Life Sci. 68:3853–3868. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Luukkaa H, Klemi P, Leivo I, et al:
Expression of matrix metalloproteinase-1, -7, -9, -13, Ki-67, and
HER-2 in epithelial- myoepithelial salivary gland cancer. Head
Neck. 32:1019–1027. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim IY, Yong HY, Kang KW and Moon A:
Overexpression of ErbB2 induces invasion of MCF10A human breast
epithelial cells via MMP-9. Cancer Lett. 275:227–233. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tan M, Yao J and Yu D: Overexpression of
the c-erbB-2 gene enhanced intrinsic metastasis potential in human
breast cancer cells without increasing their transformation
abilities. Cancer Res. 57:1199–1205. 1997.
|
|
26
|
Chua KN, Poon KL, Lim J, Sim WJ, Huang RY
and Thiery JP: Target cell movement in tumor and cardiovascular
diseases based on the epithelial-mesenchymal transition concept.
Adv Drug Deliv Rev. 63:558–567. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sethi S, Sarkar FH, Ahmed Q, et al:
Molecular markers of epithelial-to-mesenchymal transition are
associated with tumor aggressiveness in breast carcinoma. Transl
Oncol. 4:222–226. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jenndahl LE, Isakson P and Baeckström D:
c-erbB2-induced epithelial-mesenchymal transition in mammary
epithelial cells is suppressed by cell-cell contact and initiated
prior to E-cadherin downregulation. Int J Oncol. 27:439–448.
2005.
|
|
29
|
Ricono JM, Huang M, Barnes LA, et al:
Specific cross-talk between epidermal growth factor receptor and
integrin alphavbeta5 promotes carcinoma cell invasion and
metastasis. Cancer Res. 69:1383–1391. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ahmed N, Maines-Bandiera S, Quinn MA,
Unger WG, Dedhar S and Auersperg N: Molecular pathways regulating
EGF-induced epithelio-mesenchymal transition in human ovarian
surface epithelium. Am J Physiol Cell Physiol. 290:C1532–C1542.
2006. View Article : Google Scholar
|
|
31
|
Fuchs BC, Fujii T, Dorfman JD, Goodwin JM,
Zhu AX, Lanuti M and Tanabe KK: Epithelial-to-mesenchymal
transition and integrin-linked kinase mediate sensitivity to
epidermal growth factor receptor inhibition in human hepatoma
cells. Cancer Res. 68:2391–2399. 2008. View Article : Google Scholar
|
|
32
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vergara D, Merlot B, Lucot JP, Collinet P,
Vinatier D, Fournier I and Salzet M: Epithelial-mesenchymal
transition in ovarian cancer. Cancer Lett. 291:59–66. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lu YM, Zhang SL, Meng LR and Zhao YY:
Influence of human epidermal growth factor receptor-2 siRNA on
chemosensitivity to cisplatin of human ovarian carcinoma cells: an
in vitro experiment. Zhonghua Yi Xue Za Zhi. 88:909–913. 2008.(In
Chinese).
|
|
35
|
Abuharbeid S, Apel J, Zugmaier G, et al:
Inhibition of HER-2 by three independent targeting strategies
increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells.
Naunyn Schmiedebergs Arch Pharmacol. 371:141–151. 2005. View Article : Google Scholar : PubMed/NCBI
|
